Datar Cancer Genetics UK

What Datar Cancer Genetics UK does

Datar Cancer Genetics UK is a privately held molecular oncology company specialising in non-invasive cancer diagnostics based on liquid biopsy technology. Founded in India in 2013 with its primary operating entity in Guildford, UK, the company develops and commercialises a portfolio of six CE-marked blood tests that span the cancer care continuum. Its core technology combines molecular biomarker analysis with Circulating Tumour Cell (CTC) detection, covering applications from asymptomatic screening (Trucheck Intelli) and tumour diagnosis (Trublood) through comprehensive genomic profiling (Exacta and Celldx), functional chemotherapy sensitivity testing (Chemoscale), and real-time disease monitoring (Cancertrack). The company's clinical laboratory holds CLIA, CAP, CQC, and UKAS accreditations, and in 2021 received three US FDA Breakthrough Designations for breast, prostate, and brain tumour detection.

The company operates laboratories across four countries (UK, Germany, USA, India) and serves healthcare providers, clinicians, and ultimately cancer patients, symptomatic individuals, and asymptomatic high-risk populations seeking early detection. Revenue is generated on a pay-as-you-go basis per diagnostic test ordered through healthcare providers, with no publicly disclosed pricing. Go-to-market combines direct sales to clinicians and hospitals with international distribution partnerships (e.g., Virtus Group in Kuwait and South Africa) and named hospital partnerships including Cromwell Hospital and The London Clinic for second opinion services. Marketing is supported through peer-reviewed publications, medical conference participation, and digital channels targeting both providers and patients.

In early 2025 the company expanded its offering with an AI-powered decision support platform, a tumour-agnostic residual disease monitoring test, and video-enhanced chemotherapy effectiveness testing, indicating continued investment in product depth and software-enabled diagnostics layered on top of the laboratory testing core.

Name

Datar Cancer Genetics UK

Legal name

Datar Cancer Genetics Ltd.

Website

https://uk.datarpgx.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Datar Cancer Genetics UK is a privately held molecular diagnostics company offering six CE-marked liquid biopsy blood tests spanning cancer screening, diagnosis, therapy guidance, and monitoring. Operating across the UK, Germany, USA, and India, it serves healthcare providers and patients through hospital partnerships and international distributors.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics / Liquid Biopsy Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Liquid biopsy diagnostics
• Non-invasive cancer testing
• Molecular oncology diagnostics
• Circulating tumor cell analysis
• Cancer genomic profiling

Headquarters

HQ city

Guildford

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: Revenue generated from providing non-invasive cancer screening, diagnostic, and monitoring blood tests to patients through healthcare providers. Tests include Trucheck Intelli (screening), Trublood (diagnosis), Exacta/Celldx (therapy guidance), Chemoscale (chemotherapy selection), and Cancertrack (monitoring).

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Datar Cancer Genetics UK operates a molecular genetic laboratory that delivers non-invasive liquid biopsy blood tests for the full cancer care continuum. Its portfolio of CE-marked tests covers screening (Trucheck Intelli), diagnosis (Trublood), therapy guidance (Exacta, Celldx), chemotherapy selection (Chemoscale), and recurrence monitoring (Cancertrack), all based on analysis of circulating tumor cells, cell-free DNA/RNA, and tumour-associated cells from a single blood draw.

Product overview

Datar Cancer Genetics UK offers a portfolio of six CE-marked non-invasive blood tests covering the complete cancer care continuum from screening to monitoring. The portfolio includes Trucheck Intelli for early cancer screening in asymptomatic individuals, Trublood for diagnostic tumour detection as an alternative to tissue biopsy, Exacta and Celldx for comprehensive genomic profiling to guide personalized therapy selection, Chemoscale for in-vitro chemotherapy sensitivity testing, and Cancertrack for real-time monitoring of treatment response and cancer recurrence. All tests are based on analysis of circulating tumour cells, cell-free DNA/RNA, or tumour-associated cells obtained through simple blood draws, enabling liquid biopsy approaches throughout the patient journey.

Differentiator

Problem solved

Functional benefit

Brands

• Trucheck Intelli: Non-invasive blood test for early cancer detection in asymptomatic individuals by identifying cancer cells in bloodstream.
• Trublood
• Exacta
• Celldx
• Chemoscale
• Cancertrack

Products and services

• Trucheck Intelli Non-invasive blood test for early cancer screening in asymptomatic individuals. Detects and characterizes circulating tumor cells (CTCs) to identify over 70 types of solid organ cancers before symptoms appear.
• Trublood Non-invasive blood test serving as a risk-free alternative to traditional tissue biopsies for tumour detection. Uses immunocytochemistry (ICC) staining to identify circulating tumour cells, with results delivered in 10–12 days.
• Exacta Comprehensive multi-analyte genomic test integrating analysis of 400 genes and 20,802 gene expressions to identify actionable mutations, cancer-driving pathways, drug toxicity profiles, and personalised treatment recommendations for refractory cancers.
• Celldx Next-generation sequencing-based in vitro diagnostic test for comprehensive genomic profiling of solid tumours. Evaluates SNVs, InDels, CNAs, gene fusions, TMB, MSI, PD-L1 expression, and MMR status to identify guideline-recommended therapy options.
• Chemoscale Non-invasive functional test that isolates circulating tumour-associated cells (C-TACs) from blood samples and analyses their response to chemotherapy drugs in vitro to predict drug sensitivity and resistance, enabling personalised chemotherapy selection with results in 8–10 working days.
• Cancertrack Real-time non-invasive blood test that monitors cancer activity by detecting circulating tumor DNA (ctDNA) and RNA (ctRNA) to track treatment response, identify recurrence, and detect molecular changes indicating treatment resistance.
• AI-Powered Multi-Analyte Decision Support Platform AI-powered decision support platform integrating genetic and functional assay data to recommend personalised treatment for difficult-to-treat cancers.
• Video-Enhanced Chemotherapy Effectiveness Testing Video-enhanced reporting of in-vitro chemotherapy effectiveness testing, providing real-time visual documentation of chemoresponse to support treatment decisions.
• Tumor-Agnostic Residual Disease Monitoring Blood Test Tumor-agnostic plus informed blood test for residual disease monitoring using a dual-approach for early minimal residual disease detection.

Quantifiable outcome

• 94.6% overall accuracy in Trublood testing for early-stage and advanced cancers
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Cromwell HospitalcoreStrategic or Co-development Partner · 1 October 2023Trusted Second Opinion Partner providing Datar Cancer Genetics liquid biopsy testing services to patients seeking second opinions on cancer diagnosis. The partnership enables patients to access Datar's non-invasive cancer tests through Cromwell Hospital's healthcare network.
• The London CliniccoreStrategic or Co-development Partner · 1 April 2022Partnership to offer enhanced cancer testing services. The London Clinic provides access to Datar's advanced liquid biopsy diagnostics including Trucheck Intelli, Trublood, and other non-invasive cancer tests.
• Virtus GroupcoreChannel Partner/ Reseller/ Distributor · 1 December 2021Partnership to offer personalised precision oncology solutions in Kuwait. Virtus Group distributes Datar Cancer Genetics' diagnostic tests in the Kuwaiti market.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Caris Life Sciences: Caris Life Sciences offers molecular profiling services (MI Profile, Caris Assure) using both tissue and liquid biopsy for therapy selection and recurrence monitoring, overlapping directly with Datar's Exacta, Celldx, and Cancertrack portfolio.
• Personalis: Personalis provides tumor genomic profiling (NeXT Personal) and MRD/monitoring (NeXT Liquid Biopsy) using ultra-sensitive ctDNA assays, directly comparable to Datar's liquid biopsy and therapy-guidance products.
• Natera: Natera offers Signatera, a tumor-informed ctDNA test for MRD monitoring and recurrence detection, directly competing with Datar's Cancertrack product. Both companies target oncology applications of cell-free DNA/RNA analysis.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumours via FoundationOne CDx and FoundationOne Liquid CDx, directly competing with Datar's Exacta and Celldx therapy-guidance products.
• GRAIL: GRAIL develops the Galleri multi-cancer early-detection (MCED) test for asymptomatic screening, directly competing with Datar's Trucheck Intelli in the high-growth MCED category. Both companies pursue blood-based early detection across multiple solid tumour types.
• Guardant Health: Guardant Health is a leading US liquid biopsy company offering blood-based cancer diagnostics for therapy selection (Guardant360), recurrence monitoring (Guardant Reveal), and multi-cancer screening. It directly competes with Datar's Trucheck, Trublood, Exacta, and Cancertrack product lines using ctDNA-based technology.
• NeoGenomics: NeoGenomics is a US oncology-focused clinical laboratory offering comprehensive genomic profiling, liquid biopsy (RaDaR for MRD), and therapy guidance services, overlapping significantly with Datar's multi-product portfolio.
• Tempus AI: Tempus AI offers multi-modal genomic profiling, liquid biopsy (xT, xR), and AI-driven clinical decision support for oncology, directly competing with Datar's Exacta/Celldx and the newly launched AI decision support platform.

Broad incumbents

• Exact Sciences: Exact Sciences is a broader cancer diagnostics company with Cologuard (screening), Oncotype DX (therapy guidance), and the Thrive multi-cancer detection platform (acquired with Thrive Earlier Detection). Overlaps with Datar across screening and therapy guidance.

Emerging players

• Burning Rock Biotech: Burning Rock Biotech is a China-based cancer genomics company offering liquid biopsy and tissue-based NGS testing for therapy selection and MRD monitoring. Comparable technology stack and product overlap with Datar's Exacta and Cancertrack, but primarily serves the Chinese market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/datar-cancer-genetics-uk

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Datar Cancer Genetics UK